Gilead - Business Information

Q: What industry does Gilead belong to?

Gilead is in the industry of: Pharmaceuticals , Healthcare

Q: What is Gilead competition?

Gilead top competitors include: Amgen Inc , Genentech Inc , Biogen , Bristol-Myers Squibb Co

Manufacturing · California, United States · 14,400 Employees

Founded in 1987, Gilead Sciences, Inc is a biopharmaceutical company that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. The company is headquartered in Foster City, California.Read More

View Company Info for Free

Who is Gilead

Headquarters

333 Lakeside Dr, Foster City, California, 94404, United States

Phone Number

(650) 574-3000

Website

www.gilead.com

Revenue

$27.5B

Stock Symbol

GILD

Industry

Pharmaceuticals

Healthcare

Is this data correct?

View contact profiles from Gilead

Popular SearchesGILEAD SCIENCES IncGilead SciencesGileadGilead Sciences LLCGilead Sciences Pty LtdSIC Code 28,283NAICS Code 32,325Ticker NASDAQ: GILDShow More

Top Competitors of Gilead

Amgen Inc
25,200
$26.3B
1
Genentech Inc
13,500
$2.9B
2
Biogen
9,090
$10.2B
3
Bristol-Myers Squibb Co
32,200
$47B
4
Regeneron Pharmaceuticals Inc
11,851
$12.2B
5
Eisai Co. Ltd
11,322
$5.3B
6

Gilead Org Chart

Daniel O'Day

Chairman & Chief Executive O...

Phone

Anna Tuazon

Director, Chief of Staff & S...

Phone

Christopher LeMaste...

Chief Executive Officer (Xin...

Phone

Gilead Email Formats

Gilead uses at least 5 email formats with first.last (ex. John.Smith@gilead.com) being used 74.5% of the time

Gilead Email Formats		Percentage
first.last	John.Smith@gilead.com	74.5%
first + last	JohnSmith@gilead.com	0%
first_last	John_Smith@gilead.com	0%
first	John@gilead.com	0%
last	Smith@gilead.com	0%

Get Verified Emails

View Email Formats for Gilead

Gilead Company Metrics

Company Insights

Employee Growth Rate

Funding

Funding DateJan 13, 1992

RoundStock Issuance/Offering

Amount$86.3M

Investors

$86.3M

Total Funding Amount

$86.3M

Most Recent Funding Amount

Number of Funding Rounds

Acquisitions & Subsidiaries

Aug 04, 2021

XinThera

Jun 07, 2019

MiroBio

Jun 14, 2017

Tmunity Therapeutics

Feb 02, 2016

EpiTherapeutics

Corus Pharma

Eximias Pharmaceutical

See More Acquisitions & Subsidiaries

Top Companies in United States

Gilead News & Media

Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from its virology research and development programs that will be presented at IDWeek 2023, October 11-15 in Boston. These latest data demonstrate the company’s ongoing efforts to address the unmet medical needs of people and communities affected by HIV and COVID-19. Gilead will be presenting 16 abstracts, including real-world evidence, as the company continues to pursue the next wave of scientifi
Oct 3, 2023
www.businesswire.com
Gilead Board Director Kevin E. Lofton Named to List of Influential Leaders
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Kevin E. Lofton, Lead Independent Director, has been named one of the most influential leaders in corporate governance by the National Association of Corporate Directors (NACD) as part of their 2023 NACD Directorship 100™, an annual list of leading corporate directors and governance advocates. “We have been honored to have Kevin serve as the Lead Independent Director on the Gilead Board since 2020, a
Oct 2, 2023
www.businesswire.com
Why Gilead Sciences, Inc. (NASDAQ:GILD) Looks Like A Quality Company
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Sep 23, 2023
finance.yahoo.com
Sjogren's Syndrome Market Size Increase with Significant CAGR by 2032, Predicts DelveInsight | Key Companies in the Market - Resolve, MorphoSys, Novartis, GlaxoSmithKline, Roche, BMS, TearSolutions, Incyte, Galapagos, Gilead Sciences
Sjogren's syndrome market dynamics are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremental healthcare spending worldwide, and the expected launch of emerging therapies. Sjogren's syndrome market dynamics are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremental healthcare spending worldwide, and the expected launch o
Sep 21, 2023
www.globenewswire.com
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted a positive opinion for the use of Veklury® (remdesivir) to treat people with COVID-19 with mild to severe hepatic impairment. The European Commission (EC) will review the CHMP recommendation and, if adopted, Veklury will become the first and only authorized antiviral COVID-19 treatment that can be
Sep 19, 2023
www.businesswire.com